Evidence map›Paper›PMID 35419611›Full record

ArticleInternational journal of oncology2022

Machine learning with imaging features to predict the expression of ITGAV, which is a poor prognostic factor derived from transcriptome analysis in pancreatic cancer.

Yosuke Iwatate, Hajime Yokota, Isamu Hoshino, Fumitaka Ishige, Naoki Kuwayama, Makiko Itami, Yasukuni Mori, Satoshi Chiba, Hidehito Arimitsu, Hiroo Yanagibashi and 7 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yosuke IwatateDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Hajime YokotaDepartment of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan.
Isamu HoshinoDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Fumitaka IshigeDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Naoki KuwayamaDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Makiko ItamiDivision of Clinical Pathology, Chiba Cancer Center, Chiba 260‑8717, Japan.
Yasukuni MoriGraduate School of Engineering, Faculty of Engineering, Chiba University, Chiba 263‑8522, Japan.
Satoshi ChibaDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Hidehito ArimitsuDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Hiroo YanagibashiDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Wataru TakayamaDivision of Hepato‑Biliary‑Pancreatic Surgery, Chiba Cancer Center, Chiba 260‑8717, Japan.
Takashi UnoDepartment of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan.
Jason LinLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba 260‑8717, Japan.
Yuki NakamuraLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba 260‑8717, Japan.
Yasutoshi TatsumiLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba 260‑8717, Japan.
Osamu ShimozatoLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba 260‑8717, Japan.
Hiroki NagaseLaboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba Cancer Center, Chiba 260‑8717, Japan.
Chiba Cancer Center · JPChiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiogenomics has attracted attention for predicting the molecular biological characteristics of tumors from clinical images, which are originally a collection of numerical values, such as computed tomography (CT) scans. A prediction model using genetic information is constructed using thousands of image features extracted and calculated from these numerical values. In the present study, RNA sequencing of pancreatic ductal adenocarcinoma (PDAC) tissues from 12 patients was performed to identify genes useful in evaluating clinical pathology, and 107 PDAC samples were immunostained to verify the obtained findings. In addition, radiogenomics analysis of gene expression was performed by machine learning using CT images and constructed prediction models. Bioinformatics analysis of RNA sequencing data identified integrin αV (ITGAV) as being important for clinicopathological factors, such as metastasis and prognosis, and the results of sequencing and immunostaining demonstrated a significant correlation (r=0.625, P=0.039). Notably, the ITGAV high‑expression group was associated with a significantly worse prognosis (P=0.005) and recurrence rate (P=0.003) compared with the low‑expression group. The ITGAV prediction model showed some detectability (AUC=0.697), and the predicted ITGAV high‑expression group was also associated with a worse prognosis (P=0.048). In conclusion, radiogenomics predicted the expression of ITGAV in pancreatic cancer, as well as the prognosis.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsGene Expression ProfilingHumansIntegrin alphaVMachine LearningPrognosisIntegrin alphaVartificial intelligenceintegrin αVmachine learningpancreatic cancerpancreatic ductal adenocarcinomaradiogenomics

Identifiers

PMID35419611
PMCPMC8997334
OpenAlexW4223903020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.